For older adults with prior heart disease or stroke taking aspirin, 50 mg per day leads to about half the rate of bleeding and nearly double the rate of stomach problems compared to 100 mg per day.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of RCTs would determine whether the observed 47% reduction in bleeding and 94% increase in GI events with 50 mg versus 100 mg aspirin is reproducible and generalizable across diverse secondary prevention populations.
A systematic review and meta-analysis of all randomized trials comparing 50 mg and 100 mg aspirin in adults aged 60+ with prior MI, stroke, or revascularization, including at least 12,000 participants with 3-year follow-up, measuring any bleeding (BARC ≥1) and GI events (endoscopy-confirmed ulcers or hospitalizations) as primary endpoints.
A randomized trial would determine whether assigning patients with established CVD to 50 mg versus 100 mg aspirin directly causes differences in bleeding and GI event rates.
A double-blind RCT of 4,000 adults aged 60–85 with prior MI, stroke, or revascularization, randomized 1:1 to 50 mg or 100 mg aspirin daily for 3 years, with primary endpoints of any bleeding (BARC ≥1) and GI events (endoscopy-confirmed ulcers or hospitalizations), and mandatory PPI use in all participants to isolate aspirin-specific effects.
A longer-term cohort study could confirm whether the association between aspirin dose and GI events persists beyond the current 183-day median follow-up and whether bleeding risk remains stable over time.
A prospective cohort of 10,000 older Chinese adults with established CVD initiating aspirin therapy, with annual dose recording, GI symptom assessment via validated questionnaires, endoscopic follow-up in a subset, and bleeding event adjudication by independent reviewers over 5 years.
A case-control study could assess whether prior exposure to 100 mg aspirin is more common among those who developed GI ulcers or major bleeding than among matched controls.
A nested case-control study within the LAPIS cohort comparing 200 patients with GI ulcers or major bleeding to 400 matched controls without these events, assessing prior aspirin dose, duration, and concomitant NSAID or PPI use, with exposure data collected prospectively and blinded to outcome.
A cross-sectional survey could estimate the prevalence of GI symptoms among older adults currently taking 50 mg versus 100 mg aspirin, but cannot determine whether dose caused the symptoms.
A national survey of 12,000 older Chinese adults with prior CVD taking aspirin, collecting self-reported GI symptoms (heartburn, nausea, pain) and current aspirin dose via structured interviews and pharmacy records, with validation of aspirin use via blood salicylate levels in a subsample.